Q3 EPS Forecast for BioStem Technologies Raised by Analyst

BioStem Technologies, Inc. (OTCMKTS:BSEM) – Equities research analysts at Zacks Small Cap boosted their Q3 2024 earnings per share (EPS) estimates for BioStem Technologies in a report released on Thursday, October 17th. Zacks Small Cap analyst B. Sorensen now expects that the company will post earnings per share of $0.36 for the quarter, up from their previous forecast of $0.31. The consensus estimate for BioStem Technologies’ current full-year earnings is $1.13 per share. Zacks Small Cap also issued estimates for BioStem Technologies’ Q4 2024 earnings at $0.38 EPS.

BioStem Technologies Stock Down 4.3 %

Shares of OTCMKTS BSEM opened at 11.95 on Friday. BioStem Technologies has a twelve month low of 2.26 and a twelve month high of 15.50. The stock has a market cap of $194.64 million, a price-to-earnings ratio of 30.64 and a beta of 0.05. The company’s fifty day moving average is 10.84 and its 200-day moving average is 9.81.

BioStem Technologies (OTCMKTS:BSEM) last released its earnings results on Monday, August 12th. The company reported 0.30 earnings per share for the quarter, beating the consensus estimate of 0.12 by 0.18. The company had revenue of 74.49 million during the quarter, compared to analyst estimates of 43.99 million.

BioStem Technologies Company Profile

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.